explore -WSS

explore

author：leisure time 2025-10-01 17:19:10 - browse：477

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Listen: PBM conflicts, RSV vaccines, & the future of flu season

WSS

Listen: Biogen's messy board & Laronde's data problem

A new study asks: Are we harming blood donors by taking blood?

Can food be medicine? And other questions about a new push

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Why psychiatrists like me stop taking insurance

Antibiotic resistance and the global rise in human conflict

focus

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Did the public have the right to know Arthur Ashe had AIDS?

BioMarin wins approval for gene therapy to treat hemophilia A

Connecting traumatic brain injury and domestic violence

Hollywood unions extend contract negotiations for actors

Feng Zhang, Grail founder join forces on new gene editing startup

As demand for Covid shots wanes, Moderna seeks its next success

Connecting traumatic brain injury and domestic violence

Peter Hotez and the public health issue of online harassment

Make 'food is medicine' a key part of White House nutrition meeting

entertainment

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

A single drug, study failures leave Anavex with nothing but cash

7 people shot in DC, police say

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

RaDonda Vaught case: a double standard for nurses, physicians

Goldman Sachs launches $650M fund for life science investments

leisure time

hotspot

Wikipedia

Wikipedia